| Products |
Dose |
Indications |
Status |
| Approved |
| ZEGERID® (omeprazole/sodium bicarbonate) Powder for Oral Suspension |
20 mg/
1680 mg |
Heartburn/GERD, Erosive esophagitis, Duodenal ulcers |
NDA approved in June 2004; product launched in October 2004
|
| |
40 mg/
1680 mg |
Reduction of risk of upper GI bleeding in critically ill patients, Gastric ulcers |
NDA approved in December 2004; product launched in February 2005 |
| ZEGERID® (omeprazole/sodium bicarbonate) Capsules |
20 mg/
1100
mg
40 mg/
1100 mg |
Heartburn/GERD, Erosive esophagitis, Duodenal ulcers
Gastric ulcers |
NDA approved in February 2006; product launched in March 2006 |
| ZEGERID® with Magnesium Hydroxide (omeprazole/sodium bicarbonate/magnesium hydroxide) Chewable Tablets |
20 mg/
600mg/
700mg
40 mg/
600 mg/
700 mg |
Heartburn/GERD, Erosive esophagitis, Duodenal ulcers
Gastric ulcers |
NDA approved in March 2006 |
